As would be expected of infections that arise at mucosal surfaces,many studies have now demonstrated that SARS-CoV-2 induces mucosal immune responsesrevealed by the generation of secretory IgA (SIgA) antibodies in nasal, oral, andother secretions against viral antigens (reviewed in 1, 2, –, 6).Furthermore, studies of nasal or salivary IgA antibodies to SARS-CoV-2 antigens inrelation to the course of infection have shown that promptly and strongly developedmucosal IgA responses were associated with more rapid clearance of the virus andresolution of symptoms (7, 8). The gene discussed is CD79A; the disease is infection.